COCarolyn Ojano-Dirain

Carolyn Ojano-Dirain

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carolyn Ojano-Dirain has a total of 16 co-authors. Here are the top co-authors by number of shared publications:

  • Patrick J. Antonelli

    Department of Otolaryngology, College of Medicine, University of Florida, Gainesville, Florida

    14 shared publications
  • Bailey Milne-Davies

    Department of Ecophysiology, Max Planck Institute for Terrestrial Microbiology, Marburg, Germany

    2 shared publications
  • Rodrigo C. Silva

    Department of Otolaryngology, College of Medicine, University of Florida, Gainesville, FL, USA

    2 shared publications
  • Alan D. Tate

    Department of Otolaryngology-Head and Neck Surgery, University of Florida, Gainesville, Florida, USA

    1 shared publication
  • Armon Jadidian

    Department of Otolaryngology-Head and Neck Surgery, University of Florida College of Medicine, Gainesville, Florida, U.S.A.

    1 shared publication
  • Brendan Kosko

    Department of Otolaryngology-Head and Neck Surgery, College of Medicine, University of Florida, Gainesville, Florida, USA

    1 shared publication

Latest Publications

  • Cytotoxicity of Tetracyclines in Human Tympanic Membrane Fibroblasts

    by Carolyn O. Dirain, Patrick J. Antonelli

    Hypothesis: Tetracyclines are less cytotoxic to tympanic membrane (TM) fibroblasts than quinolones. Background: Use of quinolone ear drops after tympanostomy tube placement and for acute otitis externa has been linked to an increased risk of TM perforation. This has been verified in animal models. Cell culture studies have shown quinolones to be highly toxic to TM fibroblasts. Tetracyclines are a potential alternative to quinolones as they have been used to treat acute otitis externa and are thought to be nontoxic to the inner ear. We aimed to determine if tetracyclines are cytotoxic to TM fibroblasts. Methods: Human TM fibroblasts were treated with 1:10 dilutions of ofloxacin 0.3%, ciprofloxacin 0.3%, doxycycline 0.3 and 0.5%, minocycline 0.3 and 0.5%, tetracycline 0.3 and 0.5%, or dilute HCl (control), twice within 24 hours or four times within 48 hours. After 2 hours of treatment, cells were returned to growth media. Cells were observed with phase-contrast microscopy until cytotoxicity was measured. Results: Fibroblasts had lower survival with ciprofloxacin 0.3% and doxycycline 0.5% treatment compared with the control after 24 and 48 hours (all p < 0.0001). Fibroblasts treated with minocycline 0.5% had increased cell survival after 24 hours. Minocycline 0.3 and 0.5% showed increased TM fibroblast survival after 48 hours (all p < 0.0001). Phase-contrast images mirrored the cytotoxicity findings. Conclusions: Tetracyclines are less toxic to cultured TM fibroblasts than ciprofloxacin. Fibroblast tetracycline toxicity is drug and dose specific. Minocycline shows the most promise for possible otic applications in which fibroblast toxicity is a concern.


  • Rat Model of External Auditory Canal Stenosis

    by Dustin M. Lang, Patrick J. Antonelli, Carolyn O. Dirain

    Hypothesis: Circumferential electrocautery injury of the rat external auditory canal (EAC) can induce a reproducible animal model of acquired stenosis. Background: Acquired EAC stenosis may occur as a result of chronic inflammation or trauma to the EAC skin and is characterized by narrowing of the EAC, retention of debris, and hearing loss. Treatment is surgery but it is often complicated by restenosis. A reliable and inexpensive animal model of EAC stenosis has not been described. There have been no studies correlating the extent of EAC injury with the extent of stenosis. Methods: Rats received a 25, 50, or 75% circumferential EAC injury with electrocautery. The extent of resulting stenosis was quantified 21 days following injury. The nature of the injury and healing response was assessed with histology. Results: A 25% circumferential injury led to 4 to 34% stenosis (mean, 13%), 50% injury resulted in 43 to 100% stenosis (mean, 73%), and 75% injury resulted in 94 to 100% stenosis (mean=99%, p < 0.0001). The 50% circumferential injury produced 30 to 75% stenosis in five of eight ears, the remainder had >75% stenosis. Wounded ears showed evidence of intact cartilage and epithelium, with increased thickness of the subepithelial layer and localized fibrosis. Conclusions: Electrocautery injury in the ventral aspect of the rat EAC resulted in reproducible EAC stenosis. This rat model may be useful in studying therapy to prevent acquired EAC stenosis due to acute injury. The correlation of the extent of injury (circumference) with resulting stenosis may inform clinical management of EAC injuries.


  • Commercial Quinolone Ear Drops Cause Perforations in Intact Rat Tympanic Membranes

    by Carolyn O. Dirain, David N. Karnani, Patrick J. Antonelli

    Hypothesis: Commercial quinolone ear drops may promote the development of perforations (TMPs) in intact tympanic membrane (TMs). Background: Quinolone ear drops have been associated with TMPs after myringotomy +/- tube placement in a drug-specific manner and potentiation by steroids. Methods: Rats were randomized to six groups (10/group), with one ear receiving otic instillation of dexamethasone, ofloxacin, ciprofloxacin, ofloxacin + dexamethasone, ciprofloxacin + dexamethasone, or neomycin + polymyxin + hydrocortisone—all commercial formulations and at standard clinical concentrations—and the contralateral ear receiving saline, twice daily for 10 days. TMs were assessed over 42 days. Results: No TMPs were seen in ears treated with saline, dexamethasone, or neomycin. At day 10, TMPs were seen in one of 10 ofloxacin- and three of 10 ciprofloxacin + dexamethasone-treated ears (p = 0.038). At day 14, the ofloxacin TMP healed. In contrast, the three ciprofloxacin + dexamethasone TMPs remained and one new TMP developed in this group. A ciprofloxacin and an ofloxacin + dexamethasone-treated ears also had TMPs (p = 0.023). By day 21, the ofloxacin + dexamethasone TMP and two of four of the ciprofloxacin + dexamethasone TMPs healed but two new TMPs were seen in ciprofloxacin + dexamethasone ears (p = 0.0006). At day 28, 1 of 10 ciprofloxacin and 4 of 10 ciprofloxacin + dexamethasone-treated ears had TMPs (p = 0.0006). By day 35, only one ciprofloxacin + dexamethasone had TMP (p = 0.42). All TMPS were healed at day 42. Conclusions: Application of commercial quinolone ear drops can cause TMPs in intact TMs. This effect appears to be drug-specific and potentiated by steroids.


  • Effects of Common Ear Drops on Tympanic Membrane Healing in Rats

    by Carolyn O. Dirain, Brendan Kosko, Patrick J. Antonelli

    Objective: Ciprofloxacin + dexamethasone ear drops have been associated with higher rates of tympanic membrane perforations than ofloxacin. This was thought to be an effect of the steroid; however, ciprofloxacin (sans steroid) has been found to be more toxic to tympanic membrane fibroblasts than ofloxacin in vitro. This study aimed to compare the effect of these agents on tympanic membrane healing in vivo.Study Design: Controlled animal study.Setting: Academic research laboratory.Methods: Perforations were created in 54 rats with a carbon dioxide laser. Rats were randomized to 6 groups (9/group), with 1 ear receiving ofloxacin, ciprofloxacin, dexamethasone, ofloxacin + dexamethasone, ciprofloxacin + dexamethasone, or neomycin, and the contralateral ear receiving saline twice daily for 10 days. Healing was assessed over 40 days.Results: Ofloxacin did not delay healing relative to saline. All other treatments delayed healing relative to ofloxacin at day 10 (P<. 0001). Dexamethasone and ofloxacin + dexamethasone delayed healing up to day 14 (P<. 0001). Neomycin and ciprofloxacin + dexamethasone further delayed healing up to day 28 (P=. 009) and day 35 (P=. 043), respectively. All eardrums healed by day 10 with ofloxacin, day 20 with ciprofloxacin, day 28 for dexamethasone, and day 35 for ofloxacin + dexamethasone. At day 40, 2 of 9 ciprofloxacin + dexamethasone–treated eardrums had not healed. All saline‐treated eardrums in the ofloxacin, ciprofloxacin, dexamethasone, and ofloxacin + dexamethasone groups were healed by day 14, but this was delayed to day 20 in the ciprofloxacin + dexamethasone group (P=. 007).Conclusions: Ototopical quinolones delay rat tympanic membrane healing in a drug‐specific manner, with ciprofloxacin having a greater impact than ofloxacin. This effect is potentiated by steroids.


  • Cytotoxicity of Ciprofloxacin and Steroids in Mouse Tympanic Membrane Fibroblasts

    by Sonny Redula, Patrick J. Antonelli, Carolyn O. Dirain

    Objective: Ciprofloxacin, commonly given as eardrops, has been shown to adversely affect tympanic membrane fibroblasts. Dexamethasone potentiates this effect. A newly available eardrop contains ciprofloxacin and fluocinolone, a more potent steroid. We evaluated the cytotoxic effects of this preparation on mouse tympanic membrane fibroblasts.Study Design: Prospective, in vitro.Setting: Academic laboratory.Subjects and Methods: In experiment 1, fibroblasts were exposed to 1:10 dilutions of commercially available 0.3% ofloxacin, 0.3% ciprofloxacin, 0.3% ciprofloxacin + 0.1% dexamethasone, 0.3% ciprofloxacin + 0.025% fluocinolone, or dilute hydrochloric acid (control), twice within 24 hours. In experiment 2, cells were also treated with the dilutions of the pure form of dexamethasone 0.1% or fluocinolone 0.025%, alone and in combination with ofloxacin or ciprofloxacin. Cells were exposed to the solutions for 2 hours each time and were placed back in growth media after the treatments. Cells were observed with phase‐contrast microscope until the cytotoxicity assay was performed.Results: Survival of fibroblasts treated with ofloxacin was not different from the control. Fibroblasts treated with ciprofloxacin, ciprofloxacin + dexamethasone, or ciprofloxacin + fluocinolone had much lower survival (all P <. 0001). Cells treated with ciprofloxacin + fluocinolone had lower survival than ciprofloxacin (P <. 0001) and ciprofloxacin + dexamethasone (P =. 0001). Steroids alone also decreased fibroblast survival compared to control (P <. 0001). The combination of dexamethasone or fluocinolone with ciprofloxacin, but not ofloxacin, further decreased fibroblast survival (P <. 0001). Phase‐contrast images mirrored the cytotoxicity findings.Conclusion: Tympanic membrane fibroblast cytotoxicity of ciprofloxacin is potentiated by corticosteroids. This effect may be deleterious when treating a healing perforation but beneficial when treating granulation tissue on the tympanic membrane.


  • Evaluation of Mitoquinone for Protecting Against Amikacin-Induced Ototoxicity in Guinea Pigs

    by Carolyn O. Dirain, Maria Raye Ann V. Ng, Bailey Milne-Davies, Jerin K. Joseph, Patrick J. Antonelli

    Hypothesis: Mitoquinone (MitoQ) attenuates amikacin ototoxicity in guinea pigs. Background: MitoQ, a mitochondria-targeted derivative of the antioxidant ubiquinone, has improved bioavailability and demonstrated safety in humans. Thus, MitoQ is a promising therapeutic approach for protecting against amikacin-induced ototoxicity. Methods: Both oral and subcutaneous administrations of MitoQ were tested. Amikacin-treated guinea pigs (n = 12–18 per group) received water alone (control) or MitoQ 30 mg/l-supplemented drinking water; or injected subcutaneously with 3 to 5 mg/kg MitoQ or saline (control). Auditory brainstem responses and distortion product otoacoustic emissions were measured before MitoQ or control solution administration and after amikacin injections. Cochlear hair cell damage was assessed using scanning electron microscopy and Western blotting. Results: With oral administration, animals that received 30 mg/l MitoQ had better hearing than controls at only 24 kHz at 3-week (p = 0.017) and 6-week (p = 0.027) post-amikacin. With subcutaneous administration, MitoQ-injected guinea pigs had better hearing than controls at only 24 kHz, 2-week post-amikacin (p = 0.013). Distortion product otoacoustic emission (DPOAE) amplitudes were decreased after amikacin injections, but were not different between treatments (p > 0.05). Electron microscopy showed minor difference in outer hair cell loss between treatments. Western blotting demonstrated limited attenuation of oxidative stress in the cochlea of MitoQ-supplemented guinea pigs. Conclusions: Oral or subcutaneous MitoQ provided limited protection against amikacin-induced hearing loss and cochlear damage in guinea pigs. Other strategies for attenuating aminoglycoside-induced ototoxicity should be explored.


  • Mitochondria‐Targeted Antioxidant Mitoquinone Reduces Cisplatin‐Induced Ototoxicity in Guinea Pigs

    by Alan D. Tate, Patrick J. Antonelli, Kyle R. Hannabass, Carolyn O. Dirain

    Objective: To determine if mitoquinone (MitoQ) attenuates cisplatin‐induced hearing loss in guinea pigs.Study Design: Prospective and controlled animal study.Setting: Academic, tertiary medical center.Subjects and Methods: Guinea pigs were injected subcutaneously with either 5 mg/kg MitoQ (n = 9) or normal saline (control, n = 9) for 7 days and 1 hour before receiving a single dose of 10 mg/kg cisplatin. Auditory brainstem response thresholds were measured before MitoQ or saline administration and 3 to 4 days after cisplatin administration.Results: Auditory brainstem response threshold shifts after cisplatin treatment were smaller by 28 to 47 dB in guinea pigs injected with MitoQ compared with those in the control group at all tested frequencies (4, 8, 16, and 24 kHz, P =. 0002 to. 04). Scanning electron microscopy of cochlear hair cells showed less outer hair cell loss and damage in the MitoQ group.Conclusion: MitoQ reduced cisplatin‐induced hearing loss in guinea pigs. MitoQ appears worthy of further investigation as a means of preventing cisplatin ototoxicity in humans.


  • Collagen and α‐Tubulin of Mouse Tympanic Membrane Fibroblasts Treated with Quinolones and Aminoglycosides

    by Bailey A. Milne‐Davies, Patrick J. Antonelli, Nicklas C. Orobello, Carolyn O. Dirain

    Objective: To assess collagen and α‐tubulin levels of mouse tympanic membrane fibroblasts treated with quinolone and aminoglycoside antibiotics at concentrations found in eardrops.Study Design: Prospective controlled cell culture study.Setting: Academic tertiary medical center.Subjects: Mouse tympanic membrane fibroblasts.Methods: In experiment 1, fibroblasts were treated with the following for 24 or 48 hours: phosphate‐buffered saline (negative control), dilute hydrochloric acid (positive control), 0.5% gatifloxacin, or commercially available 0.3% ciprofloxacin, 0.3% ciprofloxacin + 0.1% dexamethasone, 0.3% ofloxacin, 0.5% moxifloxacin, 0.3% gentamicin, or 3.5 mg/mL of neomycin + polymyxin B sulfate + hydrocortisone. In experiment 2, cells were treated with the pure form of gatifloxacin, gentamicin, ofloxacin, or ciprofloxacin. Cells were observed with phase‐contrast microscope until harvested. Proteins were extracted for Western blotting with antibodies against collagen α1 type I (collagen 1A1) and α‐tubulin, and for densitometry to quantify levels.Results: Collagen and tubulin levels in fibroblasts treated with ofloxacin, moxifloxacin, gatifloxacin, or gentamicin for 24 hours were not different from the saline control. Fibroblasts treated with neomycin + polymyxin B + hydrocortisone, ciprofloxacin + dexamethasone, or ciprofloxacin for 24 hours had lower collagen 1A1 and α‐tubulin levels (all P <. 001) than the negative control. After 48 hours, fibroblasts treated with neomycin + polymyxin B sulfate + hydrocortisone, ciprofloxacin + dexamethasone, ciprofloxacin, or moxifloxacin had lower collagen 1A1 (P ≤. 007) and α‐tubulin (P <. 0001; except ciprofloxacin, P =. 033) as compared with control. In experiment 2, only cells treated with ciprofloxacin had lower collagen 1A1 and α‐tubulin levels and cell viability (all P <. 0001) than control. Cytotoxicity assay and phase‐contrast images mirrored the protein findings.Conclusion: The adverse impact of topical antibiotic exposure on tympanic membrane collagen and tubulin protein levels is drug specific. This may be important for selection of ototopical therapy.